Clinical trial outcomes
Uncertainty in achieving desired results.
- Materiality
- high
SynAct Pharma
SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company develops a portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases. SynAct Pharma's business model focuses on advancing projects to clinical proof-of-concept, specifically targeting Phase 2 studies, before entering commercial agreements with major pharmaceutical companies. The company is listed on Nasdaq Stockholm and operates through its subsidiaries in Denmark and Switzerland.
8
3.31
3.10
| % | |
|---|---|
| Melanocortin Agonists | 50% Includes oral and injectable compounds for inflammation resolution. |
| Clinical Development | 30% Services related to advancing clinical trials to Phase 2. |
| Research Collaborations | 20% Collaborative projects with research institutions. |
SynAct Pharma primarily targets pharmaceutical companies interested in innovative treatments for autoimmune and...
- Pharmaceutical Companiesprimary
They license therapies post proof-of-concept for autoimmune diseases.
- Research Institutionssecondary
Collaborate on developing new drug candidates.
- Biotech Firmsemerging
Interested in non-suppressive inflammation therapies.
SynAct Pharma is headquartered in Lund, Sweden, and operates through subsidiaries in Denmark and Switzerland...
- •Headquartered in Lund, Sweden
- •Subsidiaries in Denmark and Switzerland
- •Listed on Nasdaq Stockholm
- •Strong presence in the European market
- •Collaborations with European research institutions
SynAct Pharma's strategic priorities include advancing its lead compound, resomelagon, through Phase 2 clinical trials...
01
Advance resomelagon in clinical trialsmedium-term
To establish proof-of-concept and attract partners.
02
Expand therapeutic applicationslong-term
To address larger markets such as viral infections.
03
Secure strategic partnershipsshort-term
To facilitate commercialization and market entry.
Key risks for SynAct Pharma include the inherent uncertainties of drug development, such as clinical trial outcomes and...
Regulatory approval
Complex and evolving requirements.
- Materiality
- high
Competition
Other firms developing similar therapies.
- Materiality
- medium
Funding requirements
Need for continuous investment in R&D.
- Materiality
- high
R&D expense recognition
Intangible asset valuation
Revenue recognition timing
Synsam
SYNSAM.ST · Consumer Discretionary
Synsam Group is a leading optician group in the Nordic region, offering a wide range of products and services for eye health and eye fashion.
Swedish Orphan Biovitrum
SOBI.ST · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Hansa Biopharma
HNSA.ST · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
: 11/08/2026